Crescent Biopharma, Inc.
CBIO
$14.47
-$0.23-1.57%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
8/26/2025
-
Tickeron - Stocks
8/25/2025
-
TipRanks Financial Blog
8/25/2025
-
The Fly
8/23/2025
-
Tickeron - Stocks
8/22/2025
-
MarketBeat
8/18/2025
-
Seeking Alpha - Long Ideas
8/18/2025
-
SeekingAlpha
8/15/2025
-
MarketBeat
8/15/2025
-
Tickeron - Stocks
8/15/2025
-
Tickeron - Stocks
8/14/2025
-
Tickeron - Technical Analysis
8/13/2025
-
Tickeron - Stocks
8/13/2025
-
Tickeron - Stocks
8/12/2025
-
MarketBeat
8/12/2025
-
MarketBeat
8/11/2025
-
GuruFocus
8/11/2025
-
The Fly
8/8/2025
-
Tickeron - Stocks
8/7/2025
-
Tickeron - Technical Analysis
8/7/2025
-
Tickeron - Technical Analysis
8/5/2025
-
Tickeron - Stocks
8/3/2025
-
MarketBeat
8/1/2025
-
Tickeron - Stocks
7/31/2025
-
TipRanks Financial Blog
7/31/2025
-
SeekingAlpha.com: All News
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Thursday, July 31, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Jul 27 and 31 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
--
90-Day Total Return
--
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
617-430-5595
Address
300 5th Avenue
Waltham, MA 02451
Waltham, MA 02451
Country
Year Founded
--
Business Description
Sector
Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat...
more